LEXICON PHARMACEUTICALS, INC. — Director's Dealing 2025

Feb 18, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK: 0001062822
Period of Report: 2025-02-13

Reporting Person: Granowitz Craig B (SVP, Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-02-13	Stock Option (Right to Buy)	$.695	A	910170	Acquired	2035-02-13	Common Stock (910170)	Direct
2025-02-13	Restricted Stock Units	$	A	606780	Acquired		Common Stock (606780)	Direct

Footnotes

F1: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter.

F2: Each restricted stock unit represents a contingent right to receive one share of common stock.

F3: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.